CL King Initiates Coverage On Materion with Buy Rating, Announces Price Target of $95
CL King analyst David Silver initiates coverage on Materion (NYSE:MTRN) with a Buy rating and announces Price Target of $95.
B of A Securities Upgrades Dun & Bradstreet Hldgs to Neutral, Raises Price Target to $17
B of A Securities analyst Heather Bellini upgrades Dun & Bradstreet Hldgs (NYSE:DNB) from Underperform to Neutral and raises the price target from $16 to $17.
Mizuho Maintains Buy on Boston Properties, Lowers Price Target to $105
Mizuho analyst Vikram Malhotra maintains Boston Properties (NYSE:BXP) with a Buy and lowers the price target from $135 to $105.
Argus Research Downgrades McCormick & Co to Hold
Argus Research analyst John Staszak downgrades McCormick & Co (NYSE:MKC) from Buy to Hold.
Benzinga Before The Bell: FDA Temporarily Suspends Juul Ban, FTX Wants Bitcoin Derivatives, Voyager Digital Files For Chapter 11 Bankruptcy And Other Top Financial Stories Wednesday, July 6
CNBC
Ben & Jerry’s Sues Parent Unilever On Israeli business Sale
Flora Growth Appoints Brandon Konigsberg To The Board Of Directors
At the annual meeting of shareholders of Flora Growth Corp. (NASDAQ: FLGC), held on July 5, 2022, the company’s shareholders voted in favor of all of the proposals submitted for their approval.
Applied Molecular Transport Announces Top-line Phase 2 Results From MARKET Combination Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week
Caladrius Biosciences And Cend Therapeutics Highlights Publication Of Pancreatic Cancer Trial Data In The Lancet Gastroenterology And Hepatology
Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, and Cend
EF Hutton Initiates Coverage On Indonesia Energy Corp with Buy Rating, Announces Price Target of $11
EF Hutton analyst Ben Piggott initiates coverage on Indonesia Energy Corp (AMEX:INDO) with a Buy rating and announces Price Target of $11.
Morgan Stanley Maintains Equal-Weight on Cleveland-Cliffs, Lowers Price Target to $16
Morgan Stanley analyst Carlos De Alba maintains Cleveland-Cliffs (NYSE:CLF) with a Equal-Weight and lowers the price target from $24 to $16.